Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Key Takeaways Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration.The drugmaker said the twice-daily pill, Journavx, is the first such treatment to ...

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Get Wall Street's Hottest Chart Every Morning RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients who ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...